The global Controlled Substance Market is estimated to be valued at US$ 41.8 Bn in 2023 and is expected to exhibit a CAGR of 4.9% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.

Market Overview
Controlled substances refer to drugs and chemicals that are subject to special regulation due to their potential for abuse and addiction. This includes opioids, cannabis, cocaine, amphetamines, and others. They are used for medical purposes such as to relieve pain, control symptoms, and treat health conditions like cancer, diabetes, arthritis, depression, epilepsy, and others.

Market Dynamics
The growth of the controlled substance market is primarily driven by the growing prevalence of chronic diseases globally. According to WHO estimates, chronic diseases accounted for approximately 60% of all deaths worldwide in 2018. Chronic diseases require long-term or lifelong management, often through the use of controlled substances. For instance, opioids are commonly prescribed for chronic pain management resulting from diseases like cancer, arthritis, and multiple sclerosis. Furthermore, central nervous system (CNS) drugs containing controlled substances are widely used to treat neurological and mental health conditions, such as schizophrenia, depression, epilepsy, Parkinson’s disease, and multiple sclerosis.

Additionally, increasing legalization of cannabis for both medical and recreational use in various countries is another factor fueling the demand for controlled substances. According to the National Conference of State Legislatures (NCSL), as of June 2022, 38 states, District of Columbia, Guam, Puerto Rico, and U.S. Virgin Islands have legalized cannabis for medical use. Recreational use of cannabis is also permitted in 19 states and Washington D.C. Wider availability and acceptance of cannabis is expected to boost its adoption in the coming years.

SWOT Analysis

Strength: The controlled substance market benefits from strong regulations. Strict rules help ensure the quality and safety of drugs. Government policies aim to improve access to essential medicines.

Weakness: Developing new controlled substances is an expensive process. It requires extensive research and clinical trials. Counterfeit drugs undermine consumer trust in some regions. Regulations increase compliance costs for manufacturers.

Opportunity: Developing economies are growing markets for controlled medicines. Asia Pacific and Latin America offer potential for market expansion. Digital technologies can optimize supply chain management and security.

Threats: Patent expiries of blockbuster drugs lead to generic competition. This squeezes profit margins. Non-compliance with regulations may result in penalties or bans.

Key Takeaways

The Global Controlled Substance Market Demand  is expected to witness high growth, exhibiting CAGR of 4.9% over the forecast period, due to increasing prevalence of chronic diseases. As per estimates, the market was valued at US$ 41.8 Bn in 2023 and is projected to reach over US$ 58.24 Bn by 2030.

North America currently dominates the global market, accounting for over 35% revenue share in 2023. This is attributed to rising healthcare spending and the presence of advanced medical infrastructure in the US and Canada. However, Asia Pacific is poised to emerge as the fastest growing regional market during the forecast period, driven by growing medical needs of vast population, improving access to insurance, and increasing focus of international players.

Key players operating in the controlled substance market are Johnson & Johnson, Pfizer, Sanofi, Merck & Co., Gilead Sciences, Amgen, Novartis, AbbVie, GlaxoSmithKline, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, Teva Pharmaceutical, Bayer, Novo Nordisk, Allergan, Takeda Pharmaceutical, Boehringer Ingelheim, Aspen Pharmacare, Astellas Pharma. These companies dominate market sales due to their extensive product portfolios and global distribution networks. They are focusing on developing novel formulation and delivery technologies to cater to unmet medical needs.

Read More: